| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1015784915 |
| P356 | DOI | 10.1007/S00109-011-0749-Z |
| P3181 | OpenCitations bibliographic resource ID | 4322089 |
| P698 | PubMed publication ID | 21445556 |
| P50 | author | Josef Penninger | Q1674391 |
| Daniel Schramek | Q90281633 | ||
| Verena Sigl | Q96091465 | ||
| Toshikatsu Hanada | Q125250959 | ||
| P2093 | author name string | Reiko Hanada | |
| P2860 | cites work | Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations | Q24310432 |
| Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 | ||
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells | Q24315251 | ||
| Central control of fever and female body temperature by RANKL/RANK | Q24321735 | ||
| Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis | Q24324701 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 | ||
| Fever | Q24603393 | ||
| Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer | Q24605866 | ||
| GATA-3 and the regulation of the mammary luminal cell fate | Q24648936 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Cancer-related inflammation | Q27860907 | ||
| Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families | Q28137631 | ||
| Bone versus immune system | Q28140389 | ||
| Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis | Q28141482 | ||
| The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development | Q28142247 | ||
| RANK-L and RANK: T cells, bone loss, and mammalian evolution | Q28203468 | ||
| Denosumab for prevention of fractures in postmenopausal women with osteoporosis | Q28254528 | ||
| Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content | Q28270471 | ||
| RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis | Q28293009 | ||
| Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin | Q28294196 | ||
| Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems | Q28294477 | ||
| RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis | Q28294501 | ||
| Denosumab in postmenopausal women with low bone mineral density | Q28298728 | ||
| Heritable disorders of the RANKL/OPG/RANK signaling pathway | Q28299674 | ||
| Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin | Q39116155 | ||
| Regulation of cancer cell migration and bone metastasis by RANKL. | Q40298349 | ||
| Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells | Q40638246 | ||
| Mechanisms of CNS response to systemic immune challenge: the febrile response | Q40643699 | ||
| RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla | Q41868543 | ||
| Progesterone induces adult mammary stem cell expansion | Q42471079 | ||
| Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study | Q42829926 | ||
| Control of mammary stem cell function by steroid hormone signalling. | Q43103606 | ||
| Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial | Q46393065 | ||
| Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial | Q46551911 | ||
| Cytokines and fever. Mechanisms and sites of action | Q48300548 | ||
| Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. | Q50335960 | ||
| Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. | Q51803777 | ||
| The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. | Q51949099 | ||
| Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. | Q52172979 | ||
| The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. | Q53453365 | ||
| Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells | Q57184743 | ||
| Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD | Q58971166 | ||
| Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases | Q62392239 | ||
| Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer | Q68623433 | ||
| Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis | Q77435071 | ||
| Osteoimmunology: interplay between the immune system and bone metabolism | Q28303107 | ||
| IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development | Q28508430 | ||
| Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3 | Q28513448 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype | Q28609693 | ||
| Osteoclast differentiation and activation | Q29547556 | ||
| The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited | Q29547915 | ||
| Metastasis to bone: causes, consequences and therapeutic opportunities | Q29614310 | ||
| Genetic regulation of osteoclast development and function | Q29617421 | ||
| Breast cancer metastasis: markers and models | Q29618061 | ||
| Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 | ||
| Regulation of mammary gland development by tissue interaction | Q33603542 | ||
| The genetic transformation of bone biology | Q33796568 | ||
| Side-branching in the mammary gland: the progesterone-Wnt connection. | Q33843842 | ||
| Therapeutic approaches to bone diseases | Q34021178 | ||
| The role of fever in the infected host | Q34134253 | ||
| Positive and negative selection of T cells | Q34157557 | ||
| Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2 | Q34302372 | ||
| Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro | Q34459310 | ||
| Denosumab in men receiving androgen-deprivation therapy for prostate cancer | Q34570396 | ||
| Reaching a genetic and molecular understanding of skeletal development | Q34611297 | ||
| Cytokine-induced sickness behavior: mechanisms and implications | Q34631070 | ||
| Effects of denosumab on bone mineral density and bone turnover in postmenopausal women | Q34656025 | ||
| Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer | Q34813227 | ||
| Transcriptional regulators in mammary gland development and cancer | Q35097649 | ||
| Cytokines, PGE2 and endotoxic fever: a re-assessment | Q36168743 | ||
| Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE | Q36368551 | ||
| A central role for central tolerance | Q36427372 | ||
| The RANK/RANKL/OPG triad in cancer-induced bone diseases | Q36688664 | ||
| Central control of thermogenesis in mammals | Q36812556 | ||
| The role of exercise and PGC1alpha in inflammation and chronic disease | Q36984669 | ||
| RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 | ||
| New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis. | Q37748586 | ||
| An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases | Q37780489 | ||
| Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. | Q38346910 | ||
| Estrogen-progestin replacement therapy and endometrial cancer | Q38504098 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 647-56 | |
| P577 | publication date | 2011-07-01 | |
| P1433 | published in | Journal of Molecular Medicine | Q6295593 |
| P1476 | title | RANKL/RANK-beyond bones | |
| P478 | volume | 89 |
| Q24632345 | Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL |
| Q94594156 | Associations of Bone Turnover Markers with Cognitive Function in Patients Undergoing Hemodialysis |
| Q35111940 | Biotechnological approach for systemic delivery of membrane Receptor Activator of NF-κB Ligand (RANKL) active domain into the circulation. |
| Q39150873 | Bufalin attenuates cancer-induced pain and bone destruction in a model of bone cancer |
| Q58008363 | CIZ/NMP4 is expressed in B16 melanoma and forms a positive feedback loop with RANKL to promote migration of the melanoma cells |
| Q53734134 | Carnosic acid attenuates RANKL-induced oxidative stress and osteoclastogenesis via induction of Nrf2 and suppression of NF-κB and MAPK signalling. |
| Q55274553 | Cellular stress response mechanisms of Rhizoma coptidis: a systematic review. |
| Q64104002 | Effect of risperidone on proliferation and apoptosis of MC3T3-E1 cells |
| Q39159784 | Epigenetic reactivation of RANK in glioblastoma cells by curcumin: involvement of STAT3 inhibition |
| Q28247757 | Evidence for osteocyte regulation of bone homeostasis through RANKL expression |
| Q35424630 | Gene polymorphisms in RANKL/RANK/OPG pathway are associated with ages at menarche and natural menopause in Chinese women |
| Q55406267 | Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy. |
| Q91931290 | Global deletion of Optineurin results in altered type I IFN signaling and abnormal bone remodeling in a model of Paget's disease |
| Q90442956 | Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond |
| Q41137165 | IL-10 critically modulates B cell responsiveness in Rankl-/- mice. |
| Q90091707 | Immune-mediated febrile response in female rats: Role of central hypothalamic mediators |
| Q37729946 | In Vitro and In Vivo Effects of Gracilaria verrucosa Extracts on Osteoclast Differentiation |
| Q61796784 | Inflammatory and anti-inflammatory markers in plasma: from late pregnancy to early postpartum |
| Q54200830 | LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. |
| Q50513049 | LGR4: A new receptor for a stronger bone. |
| Q35894485 | Langerhans cell precursors acquire RANK/CD265 in prenatal human skin |
| Q37386814 | Markers of breast cancer stromal fibroblasts in the primary tumour site associated with lymph node metastasis: a systematic review including our case series |
| Q50884222 | Metabolic syndrome and selenium in fetal programming: gender differences. |
| Q49589290 | Morphological characteristics of osteopetrosis |
| Q39014215 | Murine Rankl-/- Mesenchymal Stromal Cells Display an Osteogenic Differentiation Defect Improved by a RANKL-Expressing Lentiviral Vector |
| Q36810697 | Muscle RANK is a key regulator of Ca2+ storage, SERCA activity, and function of fast-twitch skeletal muscles |
| Q60946525 | Mutations and Breast Cancer Prevention |
| Q48207269 | Osteoclast inhibition in postmenopausal breast cancer: Is the evidence too strong to ignore? |
| Q34017216 | Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency |
| Q35890262 | Osteoprotegerin Regulates Pancreatic β-Cell Homeostasis upon Microbial Invasion |
| Q36200053 | P2X7 Receptor Function in Bone-Related Cancer |
| Q64104436 | Plasma RANKL levels are not associated with breast cancer risk in and mutation carriers |
| Q35115616 | Prion infection of mouse brain reveals multiple new upregulated genes involved in neuroinflammation or signal transduction |
| Q64993249 | RANKL Reduces Body Weight and Food Intake via the Modulation of Hypothalamic NPY/CART Expression. |
| Q36898545 | RANKL cytokine: from pioneer of the osteoimmunology era to cure for a rare disease |
| Q47133428 | RANKL-mediated harmonious dialogue between fetus and mother guarantees smooth gestation by inducing decidual M2 macrophage polarization |
| Q60917149 | RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives |
| Q54157391 | Regulation of OPG and RANKL expressed by human dental follicle cells in osteoclastogenesis. |
| Q35721588 | Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report |
| Q90884836 | Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps |
| Q37252700 | SPARC overexpression combined with radiation retards angiogenesis by suppressing VEGF-A via miR‑410 in human neuroblastoma cells |
| Q35665655 | Selective signaling by Akt1 controls osteoblast differentiation and osteoblast-mediated osteoclast development |
| Q38719867 | Serum sRANKL and sRANKL/OPG ratio: Novel biomarkers in non-small cell lung cancer |
| Q33401086 | Severe dengue is associated with consumption of von Willebrand factor and its cleaving enzyme ADAMTS-13 |
| Q64062131 | The Molecular Mechanism of Vitamin E as a Bone-Protecting Agent: A Review on Current Evidence |
| Q35583735 | The mammalian lectin galectin-8 induces RANKL expression, osteoclastogenesis, and bone mass reduction in mice |
Search more.